RxDoctor Payments Data

Bryan To, MD

Internal Medicine · Murrieta, CANPI 1407948474

Payments from drug & device makers

$421in general payments, 2019–2025

Across 22 payments — averaging $19.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$131
  • Novo Nordisk$54
  • Pfizer$46
  • Johnson & Johnson$34
  • Lilly USA, LLC$34
  • AbbVie$34
  • plus $88 from 4 others

What the payments were for

  • Food & beverage$32176%
  • Education$10024%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$421 in reported general payments places this provider in the 65th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$37,290
Medicare patients
132
Services billed
323

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide101$100,831
JardianceEmpagliflozin95$79,003
JanuviaSitagliptin Phosphate71$72,345
EliquisApixaban50$69,697
XareltoRivaroxaban24$21,212
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$13,624
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$11,490
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog14$9,497
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog26$8,796
Breo ElliptaFluticasone/Vilanterol20$7,802
Atorvastatin Calcium578$5,192
Albuterol Sulfate HfaAlbuterol Sulfate158$4,963
Fluticasone-SalmeterolFluticasone Propion/Salmeterol31$4,438
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate12$4,429
Famotidine257$3,023

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$54$100,831101 claims
MerckJanuvia$17$72,34571 claims
PfizerEliquis$46$69,69750 claims
Johnson & JohnsonXarelto$34$21,21224 claims
AbbVieSynthroid$34$2,35628 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Murrieta

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →